Coronary artery disease: Platelet activity: an obstacle for successful PCI.
Dual antiplatelet therapy with aspirin and clopidogrel is effective in limiting adverse coronary thromboischemic events in most patients undergoing coronary stenting. However, platelet reactivity to clopidogrel is variable and stent thrombosis can occur suddenly and unexpectedly in up to 3% of patients. Is responsiveness to clopidogrel an indicator of risk of post-treatment thromboischemic events?
Gawaz
Meinrad
M
Geisler
Tobias
T
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000295:instrumentation; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000097:blood / Q000628:therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D018579:Patient Selection; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin